"CHEOPS"包用于治疗 Left Ventricular Diastolic Dysfunction 在重症患者中的管理:专家的意见
Filippo Sanfilippo1, Antonio Messina2, Sabino Scolletta3
1Department of Anaesthesia and Intensive Care, A.O.U. Policlinico-San Marco, Catania, Italy; Department of General Surgery and Medico-Surgical Specialties, School of Anaesthesia and Intensive Care, University of Catania, Catania, Italy.
Anaesthesia, critical care & pain medicine
|July 29, 2023
概括
左心室扩张性功能障碍 (LVDD) 影响重症患者. CHEOPS包提供了重症监护室中LVDD的积极管理策略,改善了患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 重症监护病房管理部门的管理.
背景情况:
- 左心室扩张性功能障碍 (LVDD) 显著影响心力衰竭的结果.
- 越来越多地认为LVDD是危急病重症监护室 (ICU) 患者预后不佳的预测因素.
- 目前严重病患者的LVDD治疗选择有限,需要积极的管理策略.
研究的目的:
- 为患有LVDD的重症患者引入一个实用的床边管理包.
- 为医生提供一个结构化的方法,以优化ICU中的LVDD管理.
- 通过积极主动的,多学科的战略来提高患者的治疗成果.
主要方法:
- 开发了CHEOPS (胸部超声波,HEmodynamics,优化通风,稳定) 软件包.
- 整合心声学和肺部超声波以进行综合评估.
- 系统评估血液动力学,机械通风,肺循环和流体管理.
- 基于专家意见的建议,用于严重疾病期间的LVDD管理.
主要成果:
- CHEOPS包为优化LVDD患者护理提供了一个框架.
- 它强调了一种主动的方法,超出了最初的复苏.
- 该包整合了重症监护的多个方面,以解决LVDD.
结论:
- 该CHEOPS捆绑提供了一个结构化的,专家推的方法来管理LVDD在重症患者.
- 这种主动策略旨在通过优化腹功能和整体血液动力学稳定性来改善结果.
- 需要进一步的验证和实施研究来证实CHEOPS包的临床实用性.
相关概念视频
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
01:29Cardiomyopathy V: Interprofessional Care
16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:25Aortic Regurgitation III: Medical Management
25
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
25